We are extremely proud that Hong Kong has ranked as the world’s #1 IPO venue in seven of the last twelve years. This success in attracting global issuers and investors is testament to the opportunities available in Asia’s most dynamic and vibrant capital markets. In 2020 a total of 154 companies raised HK$398 billion – the highest amount raised in a single year since 2010. And, despite recent global market volatility, our primary market continues to take a leading position in the world's IPO fundraising league tables.
In April 2018 we introduced new chapters to our listing rules, for the first time, opening doors to pre-revenue biotech companies and new economy companies. Since then, we have welcomed 128 new economy companies , including 28 biotech companies and 10 secondary listing companies
[1] together, raising a total of HK$554 billion.
Following Alibaba’s successful HK$101 billion listing in 2019, we continued to attract some of the world's biggest IPOs and new economy companies into our market. In 2020, we welcomed the listing of JD.com, JD Health, NetEase and Yum China, just to name a few. We remain focused on enhancing our processes and market infrastructure to make Hong Kong, and HKEX, an ever more attractive listing venue for companies from Hong Kong, Asia and around the world.
To find out more about our Markets, the benefits of "going public", the IPO process and the requirements for listing on our markets, please contact our
Global Issuer Services team.
【1】Including Zai Lab Ltd., which is classified both as biotech company and secondary listing company.
